Abstract | OBJECTIVE: METHODS: To define a role for gp130-RAPS in arthritis, a recombinant version was generated using a baculovirus expression system, and its activities were tested in vitro and in vivo. RESULTS: CONCLUSION: The use of inhibitory antibodies to block IL-6 responses has shown considerable clinical promise. However, the results presented herein suggest that selective targeting of IL-6 trans-signaling may represent a viable alternative to this strategy. In this respect, our present results suggest that the soluble gp130 isoform gp130-RAPS may be useful in the treatment of chronic inflammatory arthritis.
|
Authors | Peter J Richards, Mari A Nowell, Sankichi Horiuchi, Rachel M McLoughlin, Ceri A Fielding, Sandra Grau, Naoki Yamamoto, Michael Ehrmann, Stefan Rose-John, Anwen S Williams, Nicholas Topley, Simon A Jones |
Journal | Arthritis and rheumatism
(Arthritis Rheum)
Vol. 54
Issue 5
Pg. 1662-72
(May 2006)
ISSN: 0004-3591 [Print] United States |
PMID | 16646038
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Protein Isoforms
- Recombinant Proteins
- Cytokine Receptor gp130
|
Topics |
- Animals
- Arthritis
(drug therapy, immunology)
- Cytokine Receptor gp130
(isolation & purification, therapeutic use)
- Humans
- Mice
- Mice, Inbred C57BL
- Protein Isoforms
- Recombinant Proteins
(isolation & purification, therapeutic use)
|